GeneralMedium•10 November 2026•
1 min read
FDA Mandates New Vision Loss Warning for GLP-1 Drugs
Key Facts
1The US FDA is requiring a new warning for NAION, a potential vision loss risk, on all GLP-1 receptor agonist medications.
The US FDA is requiring a new warning for NAION, a potential vision loss risk, on all GLP-1 receptor agonist medications. Benzinga reported that the mandate applies to popular weight-loss and diabetes drugs, including Wegovy and Zepbound, which must now carry the safety notification regarding the rare eye condition.
The regulatory action follows reports and studies suggesting a potential increased risk of non-arteritic anterior ischemic optic neuropathy associated with the use of these medications. Manufacturers Novo Nordisk and Eli Lilly face this new requirement as concerns grow over long-term liability and the impact of safety mandates on the blockbuster drug class.